Therapy for H. pylori: Current concepts

Giulia Fiorini, Angelo Zullo, Valentina Castelli, Chiara Ricci, Giovanna Lo Re, Ilaria Saracino, Cristina Zaccaro, Federico Maria Verardi, Alessandra Reggi, Dino Vaira

Department of Clinical and Surgical Science, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Department of Internal Medicine, Aging and Kidney Disease, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Gastroenterology and Digestive Endoscopy, “Nuovo Regina Margherita” Hospital, Rome, Italy.
Gastroenterology Unit, University of Brescia, Brescia, Italy.

DOI: 10.4236/ojgas.2013.31006                

Abstract

Helicobacter pylori plays an important role in the pathogenesis of chronic active gastritis, peptic ulcer and gastric mucosa-associated lymphoid tissue-lymphoma, and is also involved in carcinogenesis of the stomach. Since now no current first-line therapy is able to cure the infection in all treated patients. We evaluated data on the most successful therapy regimens—sequential, concomitant and quadruple therapies—and on the standard therapy available for H. pylori eradication. When therapy fails several factors may be involved: we reviewed both bacterial and host factors that can affect the eradication and that can be involved in therapeutic management of the H. pylori infection.

Keywords

Helicobacter pylori; Sequential Therapy; Eradication

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Vakil, N. and Megraud, F. (2007) Eradication treatment for Helicobacter pylori. Gastroenterology, 133, 985-1001. doi:10.1053/j.gastro.2007.07.008
[2]	Ford, AC., Delaney, BC., Forman, D. et al. (2004) Eradication therapy in Helicobacter pylori positive peptic ulcer disease: Systematic review and economic analysis. American Journal of Gastroenterology, 99, 1833-1855. doi:10.1111/j.1572-0241.2004.40014.x
[3]	Chen, L.T., Lin, J.T., Tai, J.J., et al. (2005) Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high grade transformed MALT lymphoma. Journal of the National Cancer Institute, 97, 1345-1353. doi:10.1093/jnci/dji277
[4]	Morgner, A., Bayerdorff, E., Neubauer, A., et al. (2000) Malignant tumors of the stomach. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori. Gastroenterology Clinics of North America, 29, 593 607. doi:10.1016/S0889-8553(05)70132-1
[5]	Malfertheiner, P., Sipponen, P., Naumann, M., et al. (2005) Helicobacter pylori eradication has the potential to prevent gastric cancer: A state-of-the-art critique. American Journal of Gastroenterology, 100, 2100-2115. doi:10.1111/j.1572-0241.2005.41688.x
[6]	Stasi, R., Sarpatwari, A., Segal, J.B., et al. (2009) Effects of Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: A systematic review. Blood, 113, 1231-1240. doi:10.1182/blood-2008-07-167155
[7]	Huang, X., Qu, X., Yan, W., et al. (2010) Iron deficiency anemia can be improved after eradication of Helicobacter pylori. Postgraduate Medical Journal, 86, 272-278. doi:10.1136/pgmj.2009.089987
[8]	Malfertheiner, P., Megraud, F., O’Morain, C., et al. (2012) Current concepts in the Management of Helicobacter pylori infection: The Maastricht IV/Florence Consensus Report. Gut, 61, 646-664. doi:10.1136/gutjnl-2012-302084
[9]	Fock, K.M., Katelaris, P., Sugano, K., et al. (2009) Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. Journal of Gastroenterology and Hepatology, 24, 1587-600.
[10]	Gisbert, J.P. (2010) Sequential or concomitant therapy for Helicobacter pylori eradication? Journal of Clinical Gastroenterology, 44, 313-325.
[11]	Zagari, R.M., Bianchi-Porro, G., et al. (2007) Comparison of one and two weeks of Omeprazole, amoxicillin and Clarithromycin treatment for Helicobacter pylori eradication: The HYPER study. Gut, 56, 475-479. doi:10.1136/gut.2006.102269
[12]	Paoluzi, P., Iacopini, F., Crispino, P., et al. (2006) 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: A large prospective single-center randomized study. Helicobacter, 11, 562-568. doi:10.1111/j.1523-5378.2006.00459.x
[13]	Rokkas, T., Sechopoulos. P., Robotis, I., et al. (2009) Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third line empirical regimen. American Journal of Gastroenterology, 104, 21 25.
[14]	Katelaris, P.H., Forbes, G.M., Talley, N.J., et al. (2002) A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology, 123, 1763-1769.
[15]	Luther, J., Higgins, P.D., Schoenfeld, P.S., et al. (2010) Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. American Journal of Gastroenterology, 105, 65-73.
[16]	Malfertheiner, P., Bazzoli, F., Delchier, J.C., et al. (2011) Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin based triple therapy: A randomised, open-label, non-in feriority, phase 3 trial. Lancet, 377, 905-913. doi:10.1016/S0140-6736(11)60020-2
[17]	Gisbert, J.P. and Calvet, X. (2012) Update on non bis muth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clinical and Experimental Gastro enterology, 5, 23-34. doi:10.2147/CEG.S25419
[18]	Gisbert, J.P. and Calvet, X. (2011) Review article: Non bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Alimentary Pharmacology & Therapeutics, 34, 604-617. doi:10.1111/j.1365-2036.2011.04770.x
[19]	Zullo, A., Rinaldi, V., Winn, S., et al. (2000) A new highly effective short-term therapy schedule for Helico bacter pylori eradication. Alimentary Pharmacology & Therapeutics, 14, 715-718. doi:10.1046/j.1365-2036.2000.00766.x
[20]	Gatta, L., Vakil, N., Leandro, G., et al. (2009) Sequential therapy or triple therapy for Helicobacter pylori infection: Systematic review and meta-analysis of randomized controlled trials in adults and children. American Journal of Gastroenterology, 104, 3069-3079. doi:10.1038/ajg.2009.555
[21]	Zullo, A., De Francesco, V., Hassan, C., et al. (2007) The sequential therapy regimen for Helicobacter pylori eradication: A pooled-data analysis. Gut, 56, 1353-1357. doi:10.1136/gut.2007.125658
[22]	Murakami, K., Fujioka, T., Okimoto, T., et al. (2002) Drug ccombinations with amoxicillin reduces selection of clarithromycin resistance during Helicobacter pyloriera dication therapy. International Journal of Antimicrobial Agents, 19, 67-70. doi:10.1016/S0924-8579(01)00456-3
[23]	Houben, M., Van de Beek, D., Hensen, E., et al. (1999) A systematic review of helicobacter eradication therapy— The impact of antimicrobial resistance on eradication rates. Alimentary Pharmacology & Therapeutics, 13, 1047-1055. doi:10.1046/j.1365-2036.1999.00555.x
[24]	Cockburn, J., Gibberd, R.W., Reid, A.L., et al. (1987) Determinants of non-compliance with short term antibiotic regimens. British Medical Journal, 295, 814-818.
[25]	Labenz, J., Stolte, M., Blum, A.L., et al. (1995) Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: A study in peptic ulcer patients with omeprazole and amoxicillin. Gut, 37, 39-43.
[26]	De Francesco, V., Giorgio, F., Hassan, C., et al. (2010) Worldwide H. pylori antibiotic resistance: A systematic review. Journal of Gastrointestinal and Liver Disease, 19, 409-414.
[27]	Salama, N.R., Shepherd, B. and Falkow, S. (2004) Global transposon mutagenesis and essential gene analysis of H. pylori. Journal of Bacteriology, 186, 7926-7935. doi:10.1128/JB.186.23.7926-7935.2004
[28]	Chalker, A.F., Minehart, H.W., Hughes, N.J., et al. (2001) Systematic identification of selective essential genes in H. pylori by genome prioritization and allelic replacement mutagenesis. Journal of Bacteriology, 183, 1259-1268. doi:10.1128/JB.183.4.1259-1268.2001
[29]	Baldwin, D.N., Shepherd, B., Kraemer, P., et al. (2006) Identification of H. pylori genes contributing to stomach colonization. Infection and Immunity, 75, 1005-1016. doi:10.1128/IAI.01176-06